SCHEMBL676804

SCHEMBL676804

CCc1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.52
CYP1A2 P05177 1/20 0.48
IDO1 P14902 1/20 0.46
ALDH1A1 P00352 2/20 0.46
CHKA P35790 1/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
AGTR1 P30556 1/20 0.46
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 1/20 0.43
EGFR P00533 1/20 0.43
TAAR1 Q96RJ0 3/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A3 Q01959 2/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8990607 0.93 MAOB (0.57) MAOBCYP1A2IDO1ALDH1A1CHKA
SCHEMBL128405 0.92
Ammonia Solution, Strong SCHEMBL267275 0.89 IDO1 (0.50) IDO1ALDH1A1NPC1LMNAPOLB
Ethane SCHEMBL27746361 0.89 IDO1 (0.50) IDO1ALDH1A1NPC1LMNAPOLB
Methylamine SCHEMBL10855430 0.86 TAAR1 (0.50) IDO1ALDH1A1NPC1LMNAPOLB
SCHEMBL1702558 0.86 TP53 (0.56) ALDH1A1SMN1; SMN2TP53EGFRTAAR1
SCHEMBL2776957 0.86 TP53 (0.56) ALDH1A1SMN1; SMN2TP53EGFRTAAR1
SCHEMBL23658935 0.84 PTGS2 (0.52) MAOBCYP1A2ALDH1A1NPC1LMNA
Formaldehyde SCHEMBL28039019 0.84 ALDH1A1 (0.50) IDO1ALDH1A1NPC1LMNAPOLB
SCHEMBL14071527 0.83 CHKA (0.58) MAOBALDH1A1CHKAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174584-A1 Antibiotic Compounds UNIVERSITEIT LEIDEN (NL) 2023-06-08 US disclosed
EP-3166961-B1 N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [PSI[C(=NH) NH] TPG4] VANCOMYCIN AND [PSI[CH2NH]TPG4] VANCOMYCIN SCRIPPS RESEARCH INST (US) 2023-06-07 EP disclosed
WO-2022050369-A1 LIPOSOME PREPARATION CONTAINING ANTIBACTERIAL DRUG 国立大学法人大阪大学 2022-03-10 WO disclosed
EP-3452464-B1 PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF HOFFMANN LA ROCHE (CH) 2021-12-15 EP disclosed
EP-2651403-B1 USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES GLAXO GROUP LTD (GB) 2020-12-02 EP disclosed
WO-2018081797-A1 PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-03 WO disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed
US-20170362283-A1 NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS UNIVERSITEIT UTRECHT HOLDING B.V. (NL) 2017-12-21 US disclosed
WO-2017191098-A1 PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2017-11-09 WO disclosed
US-9802904-B2 Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-10-31 US disclosed
US-7259141-B2 Vancomycin analogs and methods thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-08-21 US disclosed
US-7259141-B2 Vancomycin analogs and methods thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-08-21 US disclosed
WO-2007084507-A2 [ψ[CH2NH]PG4] GLYCOPEPTIDE ANTIBIOTIC ANALOGS THE SCRIPPS RESEARCH INSTITUTE (US) 2007-07-26 WO disclosed
WO-2007053193-A2 UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-05-10 WO disclosed
WO-2005018743-A1 USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT THERAVANCE, INC. (US) 2005-03-03 WO disclosed
WO-2004110473-A1 USE OF A POLYENE MACROLIDE ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT THERAVANCE, INC. (US) 2004-12-23 WO disclosed
US-4027041-A Ethyl- and vinylbenzenes as antithrombotic agents ELI LILLY AND COMPANY (US) 1977-05-31 US disclosed
US-4024284-A Ethyl- and vinylbenzenes as anti-inflammatory agents ELI LILLY AND COMPANY (US) 1977-05-17 US disclosed
US-3975542-A Ethyl- and vinylbenzenes as antithromobiotic agents ELI LILLY AND COMPANY (US) 1976-08-17 US disclosed
US-3975543-A Ethyl- and vinylbenzenes as anti-inflammatory agents ELI LILLY AND COMPANY (US) 1976-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A MAOB 210/4885CYP1A2 677/4885IDO1 572/4885
US-20170362283-A1 NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS NISCH, VIP, NGLY1 MAOB 3218/4885CYP1A2 4791/4885IDO1 1023/4885
US-20230174584-A1 Antibiotic Compounds RPN1, STT3B, RPN2 MAOB 3806/4885CYP1A2 840/4885IDO1 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.